Patterns of recurrence in the basal and non-basal subtypes of triple-negative breast cancers
- PMID: 19189211
- DOI: 10.1007/s10549-008-0295-8
Patterns of recurrence in the basal and non-basal subtypes of triple-negative breast cancers
Abstract
Traditional prognostic markers for breast cancer include estrogen receptor (ER), progesterone receptor (ER) and HER2/neu. Negative staining for these three markers defines the 'triple-negative' phenotype. By adding markers for cytokeratin 5/6 and EGFR, triple-negative breast cancers can be divided into 'basal-like' and 'normal-like' subgroups. We conducted immuno-staining on a panel of 958 patients with breast cancer, using all five markers and we followed the patients for distal recurrence and death. We compared rates of distal recurrence in the basal-like and normal-like subgroups with that of women with ER-positive breast cancer. Only 16 of 958 women had normal-like breast cancers. These cancers resembled basal-like cancers in that they had a high proliferative index, but the women with normal-like breast cancers resembled ER-positive women in terms of distant recurrence. The addition of CK5/6 and EGFR to the standard panel (ER/PR/HER2/neu) defines a small subgroup of women with normal-like breast cancer. The prognosis of these women may be superior to that of basal-like breast cancers but firm conclusions cannot be made.
Similar articles
-
Basal-like immunophenotype markers and prognosis in early breast cancer.Tumori. 2010 Nov-Dec;96(6):966-70. Tumori. 2010. PMID: 21388060
-
Identification of a basal-like subtype of breast ductal carcinoma in situ.Hum Pathol. 2007 Feb;38(2):197-204. doi: 10.1016/j.humpath.2006.08.017. Hum Pathol. 2007. PMID: 17234468
-
Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.Jpn J Clin Oncol. 2012 May;42(5):375-86. doi: 10.1093/jjco/hys034. Epub 2012 Mar 26. Jpn J Clin Oncol. 2012. PMID: 22450930
-
Triple-negative breast cancer: disease entity or title of convenience?Nat Rev Clin Oncol. 2010 Dec;7(12):683-92. doi: 10.1038/nrclinonc.2010.154. Epub 2010 Sep 28. Nat Rev Clin Oncol. 2010. PMID: 20877296 Review.
-
[Basal-like breast cancer: a review].Ann Pathol. 2009 Jun;29(3):180-6. doi: 10.1016/j.annpat.2009.04.001. Epub 2009 Jun 12. Ann Pathol. 2009. PMID: 19619822 Review. French.
Cited by
-
Genetic susceptibility to triple-negative breast cancer.Cancer Res. 2013 Apr 1;73(7):2025-30. doi: 10.1158/0008-5472.CAN-12-1699. Epub 2013 Mar 27. Cancer Res. 2013. PMID: 23536562 Free PMC article. Review.
-
Breast Cancer Treatments: Updates and New Challenges.J Pers Med. 2021 Aug 19;11(8):808. doi: 10.3390/jpm11080808. J Pers Med. 2021. PMID: 34442452 Free PMC article. Review.
-
Triple-negative breast cancer: adjuvant therapeutic options.Chemother Res Pract. 2011;2011:696208. doi: 10.1155/2011/696208. Epub 2011 Jun 21. Chemother Res Pract. 2011. PMID: 22312556 Free PMC article.
-
Blocking LBH expression causes replication stress and sensitizes triple-negative breast cancer cells to ATR inhibitor treatment.Oncogene. 2024 Mar;43(12):851-865. doi: 10.1038/s41388-024-02951-3. Epub 2024 Jan 31. Oncogene. 2024. PMID: 38297083
-
USP7 Deregulation Impairs S Phase Specific DNA Repair after Irradiation in Breast Cancer Cells.Biomedicines. 2024 Mar 29;12(4):762. doi: 10.3390/biomedicines12040762. Biomedicines. 2024. PMID: 38672118 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous